Ginsenoside Ro ameliorates cognitive impairment and neuroinflammation in APP/PS1 mice via the IBA1/GFAP-MAPK signaling pathway
These findings provide strong evidence supporting Ginsenoside Ro as a potential therapeutic agent for Alzheimer's disease. Its effects appear to be mediated through the modulation of the IBA1/GFAP-MAPK pathway, which may offer new insights into AD treatment strategies.
Authors
- Qiqing Wu
- Jinman Liu (ORCID: https://orcid.org/0000-0002-6421-7482)
- Jiansong Fang (ORCID: https://orcid.org/0000-0002-6998-5384)
- Tianyao Li
- Xinyue Cao (ORCID: https://orcid.org/0000-0003-2796-6326)
- Ziying Chen (ORCID: https://orcid.org/0000-0002-6627-5176)
- Zhouyuan Xie
- Qi Wang (ORCID: https://orcid.org/0000-0001-7626-676X)
- Jiaxin Chen (ORCID: https://orcid.org/0000-0002-9119-9988)
- Yi-Yun Wang (ORCID: https://orcid.org/0000-0002-3197-5017)
- Qiqi Fan (ORCID: https://orcid.org/0000-0003-0513-5484)
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Jiangmen Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-02-24
- DOI
- https://doi.org/10.3389/fphar.2025.1528590
- Citations
- 10
- Primary Topic
- Ginseng Biological Effects and Applications
- Type
- article
- Field-Weighted Citation Impact
- 8.06
Funders
- China Postdoctoral Science Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province